Treatment Patterns and Healthcare Resource Utilization Among Patients with Atopic Dermatitis: A Retrospective Cohort Study Using German Health Claims Data

[1]  J. Jacob,et al.  Sampling strategy, characteristics and representativeness of the InGef research database. , 2021, Public health.

[2]  G. Fabbrocini,et al.  Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32‐week real‐world experience during the COVID‐19 pandemic , 2021, Clincal and Experimental Dermatology.

[3]  I. Baiardini,et al.  Atopic Dermatitis and Patient Perspectives: Insights of Bullying at School and Career Discrimination at Work , 2021, Journal of asthma and allergy.

[4]  G. Fabbrocini,et al.  Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16‐week real‐life experience during the COVID‐19 pandemic in Italy , 2021, Dermatologic therapy.

[5]  G. Argenziano,et al.  Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study , 2021, American Journal of Clinical Dermatology.

[6]  T. Bieber,et al.  Cost‐of‐illness of atopic dermatitis in Germany: data from dermatology routine care , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  J. Schmitt,et al.  Aktualisierung„ Systemtherapie bei Neurodermitis“ zur S2k‐Leitlinie Neurodermitis , 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[8]  G. Argenziano,et al.  Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  T. Luger,et al.  The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey , 2020, Dermatology and Therapy.

[10]  A. Paller,et al.  New Treatments in Atopic Dermatitis. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  M. Worm,et al.  Modern therapies in atopic dermatitis: biologics and small molecule drugs , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[12]  V. Sikirica,et al.  Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database , 2020, Dermatology and Therapy.

[13]  C. Flohr,et al.  The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate‐to‐severe atopic eczema* , 2020, The British journal of dermatology.

[14]  J. Simon,et al.  Atopic dermatitis and psychosocial comorbidities , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[15]  A. Sicras-Mainar,et al.  Severe Atopic Dermatitis In Spain: A Real-Life Observational Study , 2019, Therapeutics and clinical risk management.

[16]  K. Schäkel,et al.  Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[17]  J. Silverberg,et al.  A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[18]  T. Agner,et al.  EUROSTAD prospective observational study: Baseline characteristics, atopic dermatitis severity, and patient-reported outcomes , 2019, Journal of the American Academy of Dermatology.

[19]  H. van Os-Medendorp,et al.  Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment. , 2019, Acta dermato-venereologica.

[20]  K. Arima,et al.  Health‐care resource use and current treatment of adult atopic dermatitis patients in Japan: A retrospective claims database analysis , 2019, The Journal of dermatology.

[21]  K. Tasanen,et al.  Adult Patients with Atopic Eczema have a High Burden of Psychiatric Disease: A Finnish Nationwide Registry Study. , 2019, Acta dermato-venereologica.

[22]  L. Skov,et al.  Demographics, healthcare utilization and drug use in children and adults with atopic dermatitis in Denmark: a population‐based cross‐sectional study , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[23]  M. Ardeleanu,et al.  Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS‐J): Baseline characteristics, treatment history and disease burden , 2019, The Journal of dermatology.

[24]  A. Armstrong,et al.  Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis , 2019, PloS one.

[25]  S. Feldman,et al.  Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis , 2018, JAMA dermatology.

[26]  A. Muraro,et al.  Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[27]  D. Margolis,et al.  Epidemiology of atopic dermatitis in adults: Results from an international survey , 2018, Allergy.

[28]  A. Muraro,et al.  Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[29]  M. Lebwohl,et al.  A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis , 2017, Journal of the American Academy of Dermatology.

[30]  J. Gelfand,et al.  The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey , 2018, Journal of the American Academy of Dermatology.

[31]  Alvin W. Li,et al.  Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review , 2017, JAMA dermatology.

[32]  J. Chao,et al.  Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases , 2017, Advances in Therapy.

[33]  C. Flohr,et al.  Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey , 2017, Journal of the American Academy of Dermatology.

[34]  P. Elsner,et al.  Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany , 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[35]  Erika Sevetson,et al.  The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. , 2017, The Journal of investigative dermatology.

[36]  Jan Zeidler,et al.  Grundlagen und Methoden von GKV-Routinedatenstudien , 2014 .

[37]  C. Motala,et al.  Management of difficult-to-treat atopic dermatitis. , 2013, The journal of allergy and clinical immunology. In practice.

[38]  M. Schlaud,et al.  Prevalence and risk factors of atopic diseases in German children and adolescents , 2012, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[39]  D. Staab,et al.  Die geschätzten Kosten von Neurodermitis bei Kindern , 2000, Zeitschrift für Gesundheitswissenschaften = Journal of public health.

[40]  Torsten Zuberbier,et al.  Patient perspectives on the management of atopic dermatitis. , 2006, The Journal of allergy and clinical immunology.

[41]  J. Ring,et al.  Krankheitskostenstudie bei Patienten mit atopischem Ekzem in Deutschland , 2005, Der Hautarzt.

[42]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[43]  J. Ring,et al.  [Cost-of-illness study in patients suffering from atopic eczema in Germany]. , 2005, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[44]  H. Sampson,et al.  Atopic dermatitis and asthma: parallels in the evolution of treatment. , 2003, Pediatrics.

[45]  M. Wickman,et al.  The costs of atopy and asthma in children: Assessment of direct costs and their determinants in a birth cohort , 2003, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[46]  A. Ehlers,et al.  Cost evaluation in atopic eczema , 1999 .

[47]  P. Adnitt,et al.  Economic impact of psoriasis treatment on the patient and on the National Health Service , 1999 .

[48]  C. Steiner,et al.  Comorbidity measures for use with administrative data. , 1998, Medical care.

[49]  I I Lelis,et al.  [Atopic dermatitis]. , 1980, Vestnik dermatologii i venerologii.